CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 668 enrolled / 668 target
Drug / intervention
Atezolizumab +1 moredrug
Likely dose
Atezolizumab 1200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04102098
NCT04102098Phase 3CompletedMonitor (8.6/mo)Completion was 44mo ago
CompareCT.gov

A Phase III, Multicenter, Randomized, Open-Label Study of Atezolizumab (Anti-PD-L1 Antibody) Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation

Hoffmann-La Roche·interventional·Posted Sep 25, 2019·Updated Jun 18, 2026

In Brief

A Phase 3 clinical trial evaluating Atezolizumab and Bevacizumab for Carcinoma, Hepatocellular. Completed, enrolled 668 participants across 134 sites in 26 countries.

Signals

Enrolling slower than its timeline implies

Detailed Summary

This study will evaluate the efficacy and safety of adjuvant therapy with atezolizumab plus bevacizumab compared with active surveillance in participants with completely resected or ablated hepatocellular carcinoma (HCC) who are at high risk for disease recurrence.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Hepatocellular
CountriesAustralia, Austria, Belgium, Brazil, Canada, China, Costa Rica, Czechia, France, Germany, Hong Kong, Italy, Japan, Mexico, Netherlands, New Zealand, Peru, Poland, Russia, Singapore, South Korea, Spain, Taiwan, Thailand, Turkey (Türkiye), United States
Collaborators--

Timeline

Phase 3CompletedFinished
2020202120222023202420252026
First PostedSep 25, 2019
Enrollment StartDec 31, 2019
Primary CompletionOct 21, 2022
Study CompletionMay 15, 2026
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 6.8 years ago

Arms & Interventions

Arm A (atezolizumab plus bevacizumab)experimental

Participants will receive Atezolizumab + Bevacizumab until disease recurrence or unacceptable toxicity.

Drug: AtezolizumabDrug: Bevacizumab
Arm B (active surveillance)no_intervention

Active surveillance of participants.

Interventions

Atezolizumabdrug

Atezolizumab 1200 mg will be administered by IV infusion on Day 1 of each 21-day cycle.

Bevacizumabdrug

Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.